Biotech Venture Funding March 2026
Private financings from March 2026 — Company, date, round, investors, therapeutic area, and a one-line "what they do."
Latest VC deals here →
2026 VC Tracker
Last updated:
26 Apr 2026
March 2026
Ambrosia Biosciences
Series B
Date:
31-Mar-2026
|
Size:
US$100M
|
Therapeutic area:
Cardiometabolic / obesity
Investors:
Co-led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital; participation from BVF Partners, Boulder Ventures, Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor
What they do:
Biotech developing oral small-molecule cardiometabolic therapies, led by an oral GLP-1 receptor agonist the company says has best-in-class potential. Proceeds will support advancement of the lead oral obesity program and other cardiometabolic assets into clinical development.
Oncomatryx
Series B
Date:
30-Mar-2026
|
Size:
US$67M
|
Therapeutic area:
Oncology / tumour-microenvironment ADCs
Investors:
Spanish government-backed and regional investors including CDTI, Kutxa Fundazioa, the Basque Government, Ekarpen VC, BBK, and others
What they do:
Spanish biotech developing ADCs that target the tumour microenvironment, with a focus on cancer-associated fibroblasts. Proceeds will support clinical development of lead candidate OMTX705 and help advance OMTX105 and additional Quantum ADC programs into clinical trials.
Pinnacle Medicines
Series B
Date:
26-Mar-2026
|
Size:
US$89M
|
Therapeutic area:
Oral peptide therapeutics (immunology + cardiometabolic)
Investors:
Co-led by Lilly Asia Ventures (LAV) and Foresite Capital; participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and existing investors including OrbiMed
What they do:
Biotech developing a new generation of oral peptide medicines designed to combine biologic-level efficacy with the convenience of oral dosing. Proceeds will support lead programs through clinical proof of concept, initially focused on immunology and cardiometabolic diseases, and expand its AI- and physics-based peptide discovery platform.
Gilgamesh Pharma
Series A
Date:
24-Mar-2026
|
Size:
US$60M
|
Therapeutic area:
CNS / neuropsychiatry
Investors:
Led by Satori Neuro; participation from new and existing institutional investors including Prime Movers Lab
What they do:
Clinical-stage neuroscience company developing novel therapies for psychiatric and neurological disorders. Lead asset blixeprodil (GM-1020), an oral NMDA receptor antagonist for major depressive disorder, is expected to enter late-stage development in 2026; proceeds also support GM-3009 and broader discovery work.
Immutrin
Series A
Date:
24-Mar-2026
|
Size:
£65M (US$87M)
|
Therapeutic area:
Cardiovascular / amyloidosis
Investors:
Led by Frazier Life Sciences; participation from F-Prime, Qiming Venture Partners, SR One, Cambridge Innovation Capital, and Cambridge Enterprise Ventures
What they do:
UK biotech developing next-generation antibody therapy for ATTR amyloidosis. Proceeds will take its lead antibody asset through clinical proof of concept in ATTR cardiomyopathy, with broader potential across additional amyloidosis indications.
Earendil Labs
Financing Rounds
Date:
20-Mar-2026
|
Size:
US$787M disclosed
|
Therapeutic area:
AI-driven biologics (autoimmune disease, cancer)
Investors:
Dimension Capital, DST Global, INCE Capital, Luminous Ventures, Miracle Capital, Sanofi, Biotech Development Fund (created by Hillhouse and Pfizer), alongside other new and existing investors
What they do:
AI-native biotech building next-generation antibody and biologics programs. The company said the disclosed financing rounds will scale its R&D platform, expand teams, and advance a pipeline of biologics including HXN-1001, a half-life-extended anti-TL1A antibody ready for Phase 2 development.
Crossbow Therapeutics
Series B
Date:
18-Mar-2026
|
Size:
US$77M
|
Therapeutic area:
Oncology / TCR-mimetic antibodies
Investors:
Co-led by Taiho Ventures and Arkin Bio Capital; participation from Sixty Degree Capital, Hamilton Square Partners, LifeLink Ventures, Libbs Ventures, Blood Cancer United’s Therapy Acceleration Program, and existing investors including MPM BioImpact, Pfizer Ventures, BVF Partners, Polaris Partners, Eli Lilly, and Mirae Asset Venture Investment
What they do:
Oncology company developing TCR-mimetic antibody therapies. Proceeds will support completion of the Phase 1 trial for CBX-250 in myeloid malignancies and advance additional T-Bolt immunotherapies including CBX-663.
R1 Therapeutics
Series A
Date:
17-Mar-2026
|
Size:
US$77.5M
|
Therapeutic area:
Renal / chronic kidney disease
Investors:
Co-led by Abingworth, DaVita Venture Group, and F-Prime; participation from Curie.Bio, SymBiosis, and U.S. Renal Care
What they do:
Clinical-stage biotech focused on kidney disease. Launch financing supports global development of AP306, a pan phosphate transporter inhibitor licensed from Alebund, with a Phase 2b study in hyperphosphatemia planned for later in 2026.
Vima Therapeutics
Series A Extension
Date:
11-Mar-2026
|
Size:
US$40M extension (US$100M Series A total)
|
Therapeutic area:
Neurology / movement disorders
Investors:
New investor Frazier Life Sciences; existing investors Atlas Venture, Access Industries, and Canaan Partners
What they do:
Clinical-stage biotech advancing oral therapies for movement disorders. The extension funds Phase 2 development of VIM0423 in isolated dystonia and Parkinson’s disease, with topline data from both studies expected in 1H 2027.
Prolium Bioscience
Series A
Date:
03-Mar-2026
|
Size:
US$50M
|
Therapeutic area:
Immunology / autoimmune disease
Investors:
Led by founding investor RTW Investments
What they do:
Clinical-stage biotech developing PRO-203, a potential best-in-class CD20xCD3 T-cell engager for severe autoimmune disease. The financing supports systemic sclerosis development and expansion into additional B-cell-driven autoimmune indications.
QL Biopharm
Series C
Date:
02-Mar-2026
|
Size:
US$72M+
|
Therapeutic area:
Metabolic disease / obesity
Investors:
Led by OrbiMed; additional participation from Qiming Venture Partners, 5Y Capital, Apricot Capital, Huagai Capital, with prior investors TF Capital, Lanchi Ventures, and Taiyu Investment continuing to participate
What they do:
Biopharma focused on chronic metabolic diseases. Lead asset zovaglutide (ZT002) is a monthly GLP-1 peptide in Phase 3 for weight loss in China, alongside an oral peptide obesity program and a GLP-1/FGF21 dual agonist pipeline.